论文部分内容阅读
[目的]探讨缺氧诱导因子-2α(HIF-2α)与securin在乳腺癌组织中的表达及其对无瘤生存率的意义。[方法]采用免疫组化SP法检测70例乳腺癌组织中HIF-2α和securin的表达,并分析其与乳腺癌临床疾病特征的关系及相关性。对患者进行无瘤生存期的随访,Kaplan Meier生存曲线分析HIF-2α和securin对无瘤生存期的意义。[结果]70例乳腺癌组织中HIF-2αsecurin阳性率、高表达率分别为30.0%(21/70)和34.3%(24/70)。Spearman相关分析表明,HIF-2α与securin的表达呈正相关(r=0.381,P=0.001)。Securin高表达和HIF-2α阳性与乳腺癌患者绝经情况、雌激素受体、孕酮受体、Her-2、淋巴结转移、ki67、TNM分期和肿瘤大小均无关(P>0.05)。Kaplan Meier生存曲线表明,HIF-2α阳性患者的无瘤生存期明显高于阴性患者。Cox模型多因素生存分析结果显示,HIF-2α是乳腺癌无瘤生存期的独立影响因素(P<0.05)。[结论]HIF-2α和securin与乳腺癌的发生、发展密切相关,尤其是HIF-2α可能成为判断乳腺癌术后无瘤生存率的独立有效指标。
[Objective] To investigate the expression of hypoxia-inducible factor-2α (HIF-2α) and securin in breast cancer and their significance for disease-free survival. [Methods] Immunohistochemical SP method was used to detect the expression of HIF-2α and securin in breast cancer tissues of 70 cases, and the relationship between them and clinical disease characteristics of breast cancer was analyzed. The patient was followed up for tumor-free survival, and the Kaplan Meier survival curve analyzed the significance of HIF-2α and securin for tumor-free survival. [Results] The positive rate and high expression rate of HIF-2αsecurin in 70 cases of breast cancer were 30.0% (21/70) and 34.3% (24/70), respectively. Spearman correlation analysis showed that there was a positive correlation between HIF-2α and securin expression (r=0.381, P=0.001). High expression of Securin and HIF-2α were not associated with menopause, estrogen receptor, progesterone receptor, Her-2, lymph node metastasis, ki67, TNM stage and tumor size in breast cancer patients (P>0.05). The Kaplan Meier survival curve showed that the tumor-free survival of HIF-2α positive patients was significantly higher than that of negative patients. The results of multivariate survival analysis of Cox model showed that HIF-2α was an independent factor in the tumor-free survival of breast cancer (P<0.05). [Conclusion] HIF-2α and securin are closely related to the occurrence and development of breast cancer, especially HIF-2α may be an independent and effective index to judge the disease-free survival rate after breast cancer surgery.